A pilot randomised clinical trial: flucloxacillin plus probenecid versus flucloxacillin alone for uncomplicated skin infections

INTERVENTION: Flucloxacillin 1 g twice daily orally plus probenecid 500 mg twice daily orally for 7 days Adherence will be monitored by tablet count in blister pack CONDITION: Abscess Cellulitis infected wound Skin infection PRIMARY OUTCOME: Complete resolution, improvement, no change or worsening in infection surface area, redness, swelling, pain, tenderness and purulence, and in feverishness. Surface area will be measured by FDA‐recommended width x length method. Redness, swelling and purulence will be assessed by the research assistant. Pain, tenderness and feverishness will be assessed by visual analogue scale SECONDARY OUTCOME: Mortality The presence (or not) of any treatment‐associated adverse effects, including stomach upset, vomiting, diarrhoea, headache, dizziness, rash, itch, flushing, or joint pain. The patient may also free‐text any other possible TAAE. INCLUSION CRITERIA: New onset skin infection ‐ cellulitis, abscess, wound infection Area of the infection should be at least 75 cm2 (lesion size measured by the area of redness, oedema or induration)Weight less than 120 kg Outpatient